ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1589

COVID-19 Vaccine Hesitancy in Rheumatology Patients

Rebecca Sadun1, Amanda Eudy1, Jennifer Rogers1, Kai Sun2, Lisa Criscione-Schreiber2, Mithu Maheswaranathan2, Jayanth Doss1 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, COVID-19, race/ethnicity, socioeconomic factors, Vaccination

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for nearly all patients with rheumatic diseases. However, some individuals remain hesitant to receive a COVID-19 vaccine. This study assessed the basis for COVID-19 vaccine hesitancy in rheumatology patients. This study assessed the basis for COVID-19 vaccine hesitancy in rheumatology patients seen at a large academic medical center in the Southeastern United States.

Methods: A survey was distributed electronically during the last week of December 2020 and the first week of January 2021 (when in the US, COVID-19 vaccines were available only to health professionals) to rheumatology patients at a large academic center in the Southeastern United States. Patients completed a COVID-19 vaccine belief survey, adapted from the Vaccine Hesitancy Scale (VHS), along with a demographic survey. Patients were asked whether they would get a COVID-19 vaccine and responses were dichotomized as definitely/probably vs probably not/definitely not. Descriptive statistics and logistic regression models evaluated factors associated with vaccine hesitancy.

Results: A total of 433 patients responded to the survey: 48% self-identified as having inflammatory arthritis, 83% as female, 4% as Hispanic, 10% as Black, and 50% as a member of the Democratic Party. Individuals who wanted the COVID-19 vaccine had less hesitancy on 3 survey subscales (p< 0.001). Of respondents who identified as White, 86% wanted to receive the vaccine, in comparison to 74% of respondents who identified as Black (p=0.04) (Figure 1). Patients over the age of 70, with income >$75,000, or identifying as Democrats were also more likely to desire COVID-19 vaccination. Backward regression models identified White race (OR: 4.43; 95% CI: 1.80, 10.98) and affiliation with the Democratic Party (OR: 4.20; 95% CI: 1.93, 9.20) to be independently associated with wanting the vaccine. The primary reasons cited for hesitancy were: the vaccine being “rushed” or “experimental” (34%), safety of the vaccine in the context of patients’ rheumatologic diagnoses (34%), side effects (11%), and concern for allergic reaction (8%) (Figure 2). Common reasons for vaccine-hesitant patients to consider getting the vaccine were: “evidence the vaccine is safe in patients with my rheumatic condition” (69%) and “the ACR recommends it for people with my condition” (57%) (Figure 3).

Conclusion: Rheumatology patients wanted to be vaccinated against COVID-19 at a rate that was higher than national surveys estimates (85% vs 60-69%) during the same time period. As in national surveys, White race and Democratic Party affiliation were strongly associated with rheumatology patients wanting the vaccine. More than one third of patients revealed factors related to their rheumatologic diagnosis as the primary reason for their hesitancy. Importantly, the majority of patients indicated that they would be more likely to get the COVID-19 vaccine based on recommendations from the ACR or their rheumatologist, or in the setting of evidence of vaccine safety in rheumatic conditions.

Figure 1. Vaccine hesitancy by rheumatic diagnosis, political affiliation, household income, age, and race.

Figure 2. Patients’ stated primary reason for COVID_19 vaccine hesitancy (free-response question with qualitative data coded by theme).

Figure 3. Factors rheumatology patients indicate would increase the likelihood of their opting to receive the COVID_19 vaccine in the future (multiple-choice, “select all that apply” question).


Disclosures: R. Sadun, None; A. Eudy, NIH NCATS Award Number 1KL2TR002554, 5, Pfizer, 5, Exagen, 5; J. Rogers, Exagen, 2, 5, Pfizer, 5, Eli Lilly, 2, Immunovant, 2, Northwestern University, 2; K. Sun, None; L. Criscione-Schreiber, GlaxoSmithKline, 5; M. Maheswaranathan, None; J. Doss, Pfizer, 5; M. Clowse, UCB Pharma, 2, Pfizer, 5, GSK, 2, 5.

To cite this abstract in AMA style:

Sadun R, Eudy A, Rogers J, Sun K, Criscione-Schreiber L, Maheswaranathan M, Doss J, Clowse M. COVID-19 Vaccine Hesitancy in Rheumatology Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/covid-19-vaccine-hesitancy-in-rheumatology-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-vaccine-hesitancy-in-rheumatology-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology